HOUSTON, May 19, 2026 — Veriten, a research, strategy and investment firm, today announced the initial close of its second flagship energy venture fund with over $105 million in capital commitments. Veriten develops an unbiased, long-term global outlook for energy, power, and technology and invests in companies addressing critical industry challenges and opportunities.

Fund II aims to capitalize on the success of the firm’s initial fund to accelerate scalable technology solutions for energy, power and industrial applications.  “We are super excited about Fund II and fortunate to have such great partners and supporters.  Our unique platform and team can deliver differentiated investment opportunities and value-added expertise in this exciting but rapidly changing and complex world.  When it comes to making capital allocation decisions and investments, we aspire to be the global partner and platform of choice” said Veriten CEO and founder Maynard Holt. 

Veriten’s investments are central to the mission of identifying and scaling reliable, sustainable, and economic solutions that address operating challenges or capitalize on growth opportunities.  Fund II will focus on investments that create broadly applicable solutions, which are aligned with our view of the future energy world, and have logical, multifaceted exit opportunities. Just as importantly, investments are centered on themes where Veriten and its network of leading energy, power and technology companies can provide meaningful strategic input and value.

Veriten’s overall strategy is critically supported by over 50 key strategic partnerships across the energy, power, industrial and technology complex, including upstream, midstream, downstream, chemical, oilfield and industrial services, water, nuclear, coal, fuel cell, trading, power generation, utility, hyperscaler, and other companies and organizations.

The announcement of Fund II drew support from leaders around the energy industry.

“Veriten continues to build a differentiated platform at the intersection of energy, technology and industry expertise,” said Jeff Miller, Chairman and CEO of Halliburton Company. “We were early believers in the team and their ability to identify practical solutions to real challenges across the energy value chain. As all industries increasingly adopt digital tools, automation and AI-enabled technologies to improve performance and execution, we are proud to partner with Veriten again to help accelerate high-impact solutions across the broader energy landscape.”

Mark Lashier, Chairman and CEO of Phillips 66 Company, also offered his support: “Veriten brings a thoughtful, industry-informed perspective to the technologies and businesses shaping the future of energy. Their network, market insight and strategic approach help surface solutions that improve safety, reliability, efficiency and stewardship across the broader energy and industrial value chain. We are pleased to partner with Veriten as they connect innovative companies with the operational priorities of large-scale energy businesses.”    

Christian Exshaw, Senior Executive Vice President & Group Head, Capital Markets at CIBC, added “We are at a pivotal moment in the energy markets, with increased volatility and artificial intelligence driving significant structural transformation. At CIBC, our priority is to deliver solutions that support our clients’ growth ambitions and help them manage risk against a quickly evolving backdrop. We greatly value the strategic, data-driven insights we gain from our investment in the Veriten Venture Funds.”

John Sommers, Partner, Investments at Veriten, added “Our differentiated network, research-driven process, and first principles approach to investing are having an impact across multiple verticals including traditional energy, electrification, and industrial technology. Fund II builds on that platform.  In this environment, the differentiator isn’t capital – it’s all about connectivity, deep sector expertise, and an economically-driven approach.  As new technologies and approaches develop at breakneck speed, the need for more reliable, affordable energy and power continues to grow dramatically.  The current backdrop accentuates the need for Veriten’s solution.”

About Veriten
Veriten is based in Houston, Texas and comprises 20 professionals with backgrounds drawn from investing, research, investment banking, public buyside, technology, industrial, and entrepreneurship. Veriten is employee-owned and hosts a weekly podcast called Close of Business Tuesday as well as a weekly energy thought piece entitled Super-Spiked. For more information, please visit www.veriten.com. 

Baker Botts L.L.P. served as legal counsel for Fund II.

Media Contact:
Joe Brettell
Forward Energy Public Relations
[email protected]
(571) 230-3411

SOURCE Veriten

Start-up advances mission around World Hypertension Day

SAN FRANCISCO, May 19, 2026 — Vital Signals, a health innovation company founded by technology veteran Tom Moss, today announced that it has raised over $15M in investments, led by XYZ Ventures, to support its mission to improve how people understand, engage with and manage their blood pressure and long‑term heart health.

The announcement coincides with World Hypertension Day, this year themed ‘Controlling Hypertension Together,’ highlighting the need for greater shared understanding and more proactive approaches to a condition that affects billions worldwide and remains the leading driver of serious cardiovascular outcomes. Despite its prevalence, high blood pressure is often misunderstood and addressed only after a health event occurs.

For Moss, a serial start-up entrepreneur and veteran technology leader who has shaped products at Google, Motorola, Razer and Skydio, the company’s work is deeply personal.

“High blood pressure affects more than 100 million Americans, but many people don’t realize it until it’s too late, which is why it’s called the ‘silent killer,'” said Tom Moss, CEO & Founder of Vital Signals. “After experiencing a life-threatening hypertensive crisis, I realized how little support people have to truly understand their blood pressure and what they can do to manage it. Vital Signals was built to bring clarity, convenience and control so blood pressure becomes something people can engage with confidently over time, rather than react to in moments of uncertainty.”

The investment supports Vital Signals as it brings a breakthrough technology to consumers, allowing individuals to understand their blood pressure as a critical indicator of long‑term health. Built on technical innovation and expertise, the company is advancing a new approach grounded in accuracy, insight and long‑term relevance.

“Vital Signals achieved a technological breakthrough previously assumed to be impossible,” said Ross Fubini at XYZ Ventures. “We believe it will fundamentally change how billions of people manage their long-term heart health.”

The investment marks a key milestone for Vital Signals as the company continues to build toward future developments.

About Vital Signals

Vital Signals is a health innovation company addressing one of healthcare’s most persistent challenges: how people understand and manage blood pressure over time. Founded by tech veteran Tom Moss, the company is focused on building new approaches centered on accuracy, insights and ease of use.

Contact:
Kaplow Communications
212-221-1713
[email protected]

SOURCE Vital Signals, Inc

Framework agreement with Johnson Controls outlines plans for modular data center production at dedicated factory in Arizona, expected to create more than 500 jobs

SAN FRANCISCO, May 19, 2026 — “The AI race will not be won by one-off projects,” said Dan Wright, Co-Founder and CEO of Armada. “It will be won by the companies and countries that can manufacture, deploy, and continuously improve AI infrastructure, with speed, scale and sovereignty. At Galleon Forge One, we will do what America does best: build the industrial base to win.”

Galleon Forge One will span up to 400,000 square feet, and is expected to create 500 jobs, with additional roles in the domestic supply chain. Continuous production is planned to begin in the summer and will start with Leviathan, Armada’s megawatt-scale modular data centers built for high-density AI training and inference workloads, sovereign neo-cloud, and multi-tenant compute environments.

As part of today’s announcement, Armada and Johnson Controls are unveiling a Global Framework Agreement for modular data center systems. The company is also making an investment in Armada. Johnson Controls brings deep expertise in advanced thermal management and mission-critical building systems, supported by manufacturing leadership and a global footprint that includes more than 40,000 field personnel across all key regions. This reach enables Armada to produce and deploy sovereign AI infrastructure wherever customers need it.

“Johnson Controls is working with Armada to rapidly deliver secure modular data centers at scale,” said Joakim Weidemanis, Chief Executive Officer of Johnson Controls. “Together, we have already deployed units across the United States and around the world, demonstrating the expertise and global reach required to support mission-critical environments. Johnson Controls’ differentiated technology, U.S.-based manufacturing strength and Armada’s edge computing expertise will deliver the thermal‑critical environments that perform predictably, deploy quickly, and scale with confidence.”

Armada’s Series B was co-led by Overmatch, BlackRock and 8090 Industries. It is the company’s largest round to date and heavily oversubscribed, bringing total funding to nearly half a billion dollars. New strategic investors BlackRock, Johnson Controls, NightDragon, Mitsui and Singtel Innov8 participated in the round alongside existing investors including Overmatch, 8090 Industries, Felicis, Marlinspike, Shield Capital, Lux Capital, Founders Fund, Silent Ventures, Veriten and Gladebrook.

With this raise, Armada is not just adding firepower to its balance sheet but unlocking modular data center capacity to enable organizations to achieve autonomous, AI-powered operations anywhere in the world. This ability is critical to preserving the industrial strength required to run AI at the edge, protect sensitive data, and sustain long-term operational advantage for the United States and its allies.

The company will use its Series B capital to support explosive growth, as well as new initiatives. From FY25-26 Armada recorded 540% customer bookings growth and significant interest in Leviathan. Q1 FY27 alone saw a 2000% increase in bookings growth, compared to Q1 the previous year.

Global Demand is Accelerating

Defense Edge Deployment: Armada supported an ally’s defense organization in deploying a Triton into the field in six days, demonstrating how customers can move from infrastructure need to operational capability without waiting on traditional data center construction cycles.

WinDC: WinDC selected Armada to provide the first network of portable AI factories designed to run on renewable energy that Australia’s national grid can’t absorb. As demand for real-time data processing and AI inference grows faster than centralized infrastructure supports, the customer began with a Triton and is scaling its sovereign AI infrastructure to a 10MW+ Leviathan deployment.

U.S. Navy: Armada enabled the U.S. Navy to deploy edge computing during a major multinational maritime exercise. Running mission applications including Minotaur on a Galleon aboard a communications-constrained vessel demonstrated how modular compute can support real-time decision-making, where centralized cloud infrastructure is limited or unavailable.

Aker BP: On the Norwegian Continental Shelf, Aker BP is performing building and testing, with an aim to deploy a Galleon on the Deepsea Nordkapp. Running AI models at the rig will move Aker BP and its alliance partners toward their ultimate goal of autonomous operations. Following and depending on a successful initial trial, Aker BP intends to scale AI capability across the fleet.

“At Aker BP, we are transforming how hydrocarbons are produced in the most challenging environments, and we know we cannot do it alone,” said Mads Rødsjø, VP, D&W Operations, Aker BP. “Our vision is real-time data processing, AI-ready workflows, and autonomous operations at the edge. Partnering with Armada gives us the infrastructure to make that vision a reality and scale across our fleet.”

Strategic Partnerships and Proven Deployments Drive Customer Momentum

Armada continues to expand its ecosystem and Marketplace through partnerships and collaborations with companies including Microsoft, NVIDIA, Palantir and Dell Technologies. These help customers deploy AI infrastructure faster, run workloads closer to where data is generated, and maintain control over sensitive data, models, and operations.

With dedicated Galleon manufacturing, strategic capital investments, and a growing partner ecosystem, Armada is scaling the infrastructure customers need to deploy AI across the world’s most demanding environments.

About Armada
Armada is the hyperscaler for the edge, delivering modular AI infrastructure from first deployment to AI factory with speed, scale and sovereignty. For more information, visit www.armada.ai.

Media contact: [email protected]

SOURCE Armada

SUZHOU, China and GEMBLOUX, Belgium, May 18, 2026 — Full-Life Technologies (“Full-Life“, the “Company“), a fully-integrated global radiotherapeutics company, today announced the completion of a US$150 million financing package, comprised of approximately US$110 million in Series D equity and US$40 million in debt financing. Vivo Capital led the financing, joined by Full-Life’s strategic partner SK Biopharmaceuticals Co., Ltd. and Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, as well as other renowned shareholders.

Proceeds from the Series D round will be used to advance the Company’s clinical stage assets, including potential best-in-class [225Ac]-FL-020 for prostate cancer and potential first-in-class [225Ac]-FL-261 for multiple solid tumor indications. By year-end 2026, Full-Life expects to have three differentiated clinical stage programs, all of which emerged from its UniRDC™ discovery platform. Proceeds will also facilitate the initiation of GMP-grade 225Ac manufacturing at the Company’s state-of-the-art facility in Belgium. Having isotope supply and manufacture under its complete control is a significant strategic advantage in advancing radiotherapeutics rapidly through clinical development.

“Full-Life is distinguished not only by their scientific vision, but their ability to translate it into tangible clinical and operational milestones at a global scale,” said Hao Dong, Managing Director at Vivo Capital. “We are impressed by their early discovery efficiency, the strong emerging data from their lead program, and the accelerated progress of their manufacturing facility in Belgium. Leading this Series D financing reflects our conviction that Full-Life is transitioning from a platform innovator to a fully integrated radiopharmaceutical company, and we are excited to support their next phase of value creation.”  

“This financing reflects the significant value we have created over the past four years, evolving from a platform builder to a clinical-stage company,” said Julie Wu, President and Chief Financial Officer of Full-Life. “With the strong momentum from our lead asset, and the rapid advancement of our pipeline assets, this funding will accelerate our transition toward late-stage development and ensure our Belgium GMP facility is fully operational to support global 225Ac commercial supply.”

With completion of this round, Full-Life has secured nearly US$350 million funding since its inception in 2021, including equity financing and debt financing.

About Vivo Capital

Founded in 1996, Vivo Capital is a leading global healthcare investment firm with a multi-strategy platform spanning venture capital, private equity, and public markets. The firm manages over $7.0 billion across 16 USD and RMB funds and has invested in over 460 companies worldwide. Vivo Capital focuses exclusively on the healthcare sector, including biotechnology, pharmaceuticals, medical devices, and pharma services, with an emphasis on the world’s largest and fastest-growing markets. The firm is differentiated by its “Ecosystem Strategy,” leveraging deep industry networks and operational capabilities to deliver strategic support beyond capital. Headquartered in Palo Alto, California, Vivo Capital has offices in Beijing, Shanghai, Hong Kong, Taipei, and Singapore, supported by a global team of over 70 professionals.

About Full-Life Technologies

Full-Life Technologies (“Full-Life”) is a privately held, fully-integrated clinical-stage global radiotherapeutics company with operations worldwide. Our mission is to deliver the power of radiotherapy to cancer patients worldwide by owning the entire value chain for radiopharmaceutical research & development including production & commercialization. By combining advanced manufacturing capabilities, biological insights and clinical efficiency, the Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences and unwavering dedication to patients worldwide. Learn more at: https://www.full-life.com/  

SOURCE Full-Life Technologies

• Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza
• Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis

NEW YORK and SUZHOU, China, May 18, 2026 — Accro Bioscience Inc. (“Accro Bioscience”), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune mediated diseases, announced the closing of its $50 million Series C financing. The round was led by OrbiMed, with participation from TCG Crossover (“TCGX”), LAV, Cenova Capital, and existing investors Shenzhen Capital Group (“SCGC”) and Oriza Holdings (“Oriza”).

Proceeds from the financing will fund the Phase IIb clinical trial of AC-101, a leading RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for I&I diseases.

Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accro Bioscience, said: “We at Accro Bioscience are focused on our mission of delivering innovative oral treatments for the millions of patients living with immune mediated diseases. I’m grateful to our investors who share our vision and have supported us continuously.”

Steven Wang, Ph.D., CFA, Partner at OrbiMed, said: “We are highly impressed by Accro Bioscience’s innovative pipeline. The team’s scientific acumen and track record of strong execution were instrumental in our decision to invest. OrbiMed is excited to partner with Accro to accelerate their global clinical development.”

About AC-101

AC-101 is a novel, selective RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). Receptor interacting protein kinase 2 (RIPK2) is a key mediator in the NOD signaling pathway, and dysregulation of NOD/RIPK2 is implicated in several inflammatory and autoimmune diseases. AC-101 was developed from Accro Bioscience’s proprietary drug discovery platform targeting regulatory cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The Company has received the IND clearance from U.S. FDA for a Phase II clinical trial.

About Accro Bioscience

Accro Bioscience Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for inflammatory and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death. The company’s robust pipeline of first- and best-in-class compounds offers the potential for innovative, paradigm-shifting therapies.

For more information, please visit www.accropeutics.com.

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over $19 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

For more information, please visit www.orbimed.com.

SOURCE Accro Bioscience Inc.

NORWALK, Conn., May 18, 2026 — Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics’ $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures.

Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company’s proprietary CONNECT platform is designed to identify therapeutically actionable signaling pathways that drive neuroinflammation, neurodegeneration, and synaptic loss.

Synaptic loss is one of the strongest predictors of cognitive decline in Alzheimer’s disease and other neurodegenerative conditions, and Violet’s lead program is designed to address this core pathology through glial-mediated synaptic preservation and repair. “Preserving cognitive function is one of the most important challenges in aging biology, and Violet is approaching that challenge from a uniquely actionable angle,” said Altar Munis, Associate at Lifespan Vision Ventures. “The company’s CONNECT platform gives it a systematic way to uncover how glial signaling contributes to synaptic dysfunction, with EphB3 representing a strong first step toward therapies that may protect brain health across aging and neurodegenerative disease.”

“We are pleased to welcome LVV as the lead investor in this extension round. LVV brings deep sector expertise in technologies that will impact diseases of aging and cognition. Likewise, their addition to the board adds valuable perspective as we continue to advance our EphB3 program towards the clinic and to develop our CONNECT discovery platform,” said Meredith Fisher, Partner at Mass General Brigham Ventures and CEO of Violet.

Proceeds from the financing will support advancement of Violet’s lead small molecule program targeting EphB3 through key IND-enabling activities. EphB3, a receptor tyrosine kinase implicated in microglia-astrocyte signaling, emerged directly from Violet’s CONNECT platform and represents the company’s first therapeutic target generated from its cellular connectome approach.

About Lifespan Vision Ventures

Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan.

Contact: [email protected]

About Violet Therapeutics
Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company’s proprietary CONNECT platform enables discovery of novel targets emerging from cellular interaction networks rather than genetic association alone, supporting the development of a pipeline of small-molecule therapeutics addressing neuroinflammation and related CNS pathologies.

For more information, visit www.violettx.com

Media contact:
Meredith Fisher, CEO
[email protected]

SOURCE LifeSpan Vision Ventures

HONG KONG, May 18, 2026 — AEON, the settlement layer built for the agentic economy, today announced it has successfully closed an $8 million pre-seed funding round. The round was led by YZi Labs, with participation from a robust group of leading investors, including IDG Capital, HashKey Capital, Stanford Blockchain Builders Fund, Oak Grove Ventures, SevenX Ventures, Alchemy Ventures, Draper Dragon, Contribution Capital, and Uphonest Capital.

The funding will accelerate AEON’s mission to build the financial backbone required for a new economic paradigm, where AI reshapes production relations across the internet and becomes an active participant in global commerce. AEON is building the settlement layer that this new paradigm demands, powering the agentic economy at scale, and bridging Agent-to-Agent (A2A) interactions with real-world merchant settlement.

As one of the earliest official partners of Coinbase‘s x402 protocol, AEON has been at the forefront of turning the concept of AI payments into reality. The company launched its first AI payment product in May, enabling AI agents to execute on-chain transactions and connect to over 50 million real-world merchants across the globe. With AEON, AI enters the marketplace, where ideas, intent, and intelligence can directly move value.

In partnership with BNB Chain, AEON recently launched the x402 Facilitator, built natively on the BNB Chain infrastructure. This enables verifiable transactions, on-chain settlement, and immutable receipts for millions of service providers within the BNB ecosystem, building payment infrastructure constructed for the agentic economy at internet scale.

By leveraging AI native protocols like x402, ERC-8004, Google AP2, and MCP, AEON enables autonomous and verifiable AI agent transactions that bridge the gap between digital agent interactions and real-world settlement. Its Protocol Kernel x402 Stack encapsulates payment instructions into HTTP 402 status codes, embeds settlement logic directly into every API request or service subscription, and ensures real-time clearing between A2A transactions. The distributed Trust Hub verifies transaction payloads with atomic finality, guaranteeing irreversible settlement. This architecture enables continuous value flows between agents, and through AEON’s Physical Gateway, extends into Agent-to-Merchant scenarios where agents can pay.

Building in phases, AEON’s roadmap begins with a completed foundation of cross-chain infrastructure and payment standards. It is now advancing into trust and scale, evolving from payment verification to execution verification while expanding its global settlement network across emerging markets and traditional financial rails. Looking ahead, AEON aims to unlock fully autonomous agent collaboration supported by a native KYA credit system and with full-stack AI financial services, where AI agents can coordinate, transact, and settle value across complex real-world scenarios. 

AEON’s founding team brings deep experience from Binance, Chainlink, Google, HSBC, and GrabPay, combining with deep expertise in AI, blockchain architecture, and real-world payments. This blend allows AEON to build a settlement layer the way the agentic economy actually operates, scaling payments that are verifiable, trustless, and at machine speed.

“AEON is not just bridging AI and real-world commerce, we are building the settlement layer the agentic economy inherently requires,” said Eddie Li, CEO and co-founder of AEON. “As production relations shift toward an economy powered by autonomous agents and value exchange between AIs, we believe a settlement layer built for the agentic economy will emerge and this economic paradigm needs its own financial foundation. This funding empowers us to accelerate that mission, advancing our settlement layer built for AI, and deepening collaboration with ecosystem partners like Coinbase and BNB Chain.”

About AEON

AEON is the settlement layer built for the agentic economy, leveraging leading protocols to enable autonomous, verifiable AI agent transactions at scale. It bridges Agent-to-Agent (A2A) interactions with real-world settlement and continuous value flows.

Serving more than 2 million users and processing 30M monthly transactions, AEON is backed by YZi Labs and IDG Capital, with participation from investors including HashKey Capital, Stanford Blockchain Builders Fund, etc.

Website | X | Telegram | Medium | AEON Pay

About YZi Labs

YZi Labs manages over $10 billion in assets globally. Our investment philosophy emphasizes impact first—we believe that meaningful returns will naturally follow. We invest in ventures at every stage, prioritizing those with solid fundamentals in Web3, AI, and biotech.

YZi Labs’ portfolio covers over 300 projects from over 25 countries across six continents. Some notable portfolios include Trustwallet, CoinMarketCap, Polygon, Injective, Ethena, Safepal Wallet, Better Payment Network, Aster, XAI (acquired by SpaceX), and more. More than 65 of YZi Labs’ portfolio companies have gone through our incubation program, EASY Residency. For more information, follow YZi Labs on X. 

SOURCE AEON

Financing and expanded board leadership position the company to accelerate FDA clearance and commercialization of its novel imaging system

SUNNYVALE, Calif. and GIVATAYIM, Israel, May 18, 2026 — Vortex Imaging Inc. announced today the closing of a $12 million financing round, supported by existing and new investors, including 10D Ventures, Entrée Capital, Harel T.E.C Partnership, Connecticut Innovations, and PhiFund Ventures.

The financing will support the continued development, regulatory clearance, and market launch of Vortex Imaging’s computational ultrasound system, a novel imaging technology designed to enable high-quality 3D volumetric imaging at the point of care using pioneering computational image reconstruction technology, utilizing GPUs-on-Cloud.

Today, many advanced imaging workflows rely on centralized radiology suites, which can contribute to delays in access to imaging and patient care. Vortex Imaging is developing a compact ultrasound-based imaging system designed to bring advanced 3D volumetric imaging into everyday clinical settings. The system aims to reduce variability associated with conventional ultrasound workflows by enabling standardized, reproducible volumetric datasets with a reduced learning curve, while avoiding ionizing radiation and large imaging infrastructure.

The reconstructed images are intended to provide physicians with advanced 3D volumetric visualization capabilities in a format traditionally associated with CT and MRI, while maintaining the accessibility, safety, and portability advantages of ultrasound.

“This financing round marks a major milestone for Vortex Imaging,” said Tomer Ben David, CEO of Vortex Imaging. “Vortex is focused on transforming ultrasound from a highly operator-dependent modality into a standardized, volumetric imaging system capable of delivering advanced 3D clinical insights directly at the point of care. We are excited to have the support of experienced investors and board members as we continue advancing toward FDA clearance and initial clinical deployment.”

In addition, Ori Hadomi, former CEO of Mazor Robotics and current Vice President of Strategic Initiatives & Partnerships at Medtronic, has been appointed Chairman of the Board, bringing significant experience in guiding transformative medical technologies from development to global commercialization.

The board will also include experienced healthcare and medtech leaders, including Chris Cleary, former Vice President of Corporate Development at Medtronic and former GE Healthcare executive; Yahal Zilka, co-founder and Managing Partner at 10D Ventures; and Dr. Yael Grunbaum, Partner at Entree Capital and Head of Entrée Bio.

Together, the expanded board brings deep expertise across medical imaging, strategic growth, corporate development, and commercialization of global medtech platforms.

Vortex Imaging’s initial clinical focus is on urology and nephrology, with broader future applications planned across additional diagnostic and procedural domains.

“Vortex Imaging has the potential to significantly expand how and where advanced imaging is performed,” said Ori Hadomi, Chairman of the Board. “The combination of high-quality volumetric imaging, reduced operator dependency, and a compact ultrasound-based platform could enable a far more scalable and standardized approach to imaging across healthcare systems.”

For more information visit: https://www.vortex-imaging.com/ or LinkedIn.

Watch: Why wait for imaging? 

Contact:
Izik Ithakov
[email protected]

SOURCE Vortex Imaging Inc.

GERMANTOWN, Wis., May 18, 2026 — Innovative Motion Technologies (IMT), a global industrial technology platform and Cathay Capital portfolio company, today announced the successful closing of a new senior credit facility led by TPG Twin Brook. The financing supports IMT’s continued growth and buy-and-build strategy across diversified end markets including healthcare, industrial, HVAC, and utilities.

The new financing strengthens the company’s capital structure and provides additional flexibility to invest in its vertically integrated platform, expand engineering capabilities, pursue strategic and synergistic acquisitions, and broaden its product offering across key end markets, including healthcare, industrial, HVAC, and utilities. The financing was led by TPG Twin Brook, which served as sole lender.

“This financing enables us to continue investing in the business while expanding our product offering across both existing and new end markets,” said Rich Weeden, CEO of IMT. “We remain focused on building on our platform, supporting customers across our diversified end markets, and driving continued growth across the business.”

Andrew Hartinger, CFO of IMT, added “We are pleased to have completed this financing with a top-tier lending partner, which provides significant capacity to execute IMT’s buy-and-build strategy.”

“Since our investment in IMT, the Company has evolved into a differentiated global platform in interface and control technologies, supported by best-in-class engineering and a scaled, diversified footprint across attractive end markets,” said Mark Woods, Partner at Cathay Capital. “This financing enhances IMT’s ability to accelerate growth and deliver on its long-term value creation strategy.”

Piper Sandler served as sole debt placement agent on the transaction.

About Innovative Motion Technologies

Innovative Motion Technologies (IMT) is a global industrial technology platform and industry-leading designer and supplier of advanced motion control and interface solutions across a diversified set of OEM and aftermarket applications. The Company operates through a family of brands to deliver highly engineered products across multiple end markets worldwide. For more information, please visit https://imtbrands.com.

About Cathay Capital

Cathay Capital is a global private equity and venture capital investment firm supporting healthcare, technology and consumer companies throughout North America, Europe, and Asia. The firm helps middle-market companies and startups navigate opportunities for growth, international expansion, and sustainable transformation. Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its platform connects people with global reach and local expertise – from investors and entrepreneurs to management teams and leading corporations – to share knowledge, the tools to scale and to transform businesses.

Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages more than $5.5 billion in assets. It has made over 250 investments in verticals including healthcare, technology, and consumer from offices in New York, San Francisco, Paris, Munich, Berlin, Madrid, Shanghai, Beijing, Shenzhen, and Singapore.

For more information, visit: www.cathaycapital.com.

Media Contact:
Mary Magnani, CodePR
[email protected]

SOURCE Cathay Capital